Javascript must be enabled to continue!
General immunologic reactivity of patients with COVID-19 and its relation to gene polymorphism, severity of clinical course of the disease and combination with comorbidities
View through CrossRef
The aim of the study is to identify and evaluate the general immunological reactivity of patients with COVID-19 and its relationship with gene polymorphism, severity of the clinical course of the disease and combination with comorbidities. A cohort study was conducted involving 204 patients with COVID-19 diagnosed with community-acquired pneumonia of mild, moderate, and severe degrees who also had comorbidities: endocrinopathies (46 patients), cardiovascular diseases (82 patients), and comorbidities of the ENT organs, connective tissue, gastrointestinal tract, chronic kidney disease (CKD), which were grouped into the group "other comorbidities (76 patients). Among the patients there were 51.97% (106) women and 48.03% (98) men. The average age of patients was 55.93±8.75 years. The polymorphism of the NOS3 (rs2070744), FGB (rs1800790) and TMPRSS2 (rs12329760) genes was determined by real-time polymerase chain reaction (qualitative determination). The overall immunological reactivity was detected and evaluated based on the analysis of 14 integral leukocyte indices: leukocyte shift index, absolute leukocyte count/erythrocyte sedimentation rate (ESR) ratio index, lymphocyte-granulocyte index, lymphocyte index, immunological resistance and reactivity index, and others. The overall immunological reactivity of the body of patients with coronavirus infection increases in the presence of the wild-type T-allele of the eNOS gene (rs2070744) in the patient's genotype, especially the CC genotype, by 21.98-57.89% (p≤0.029-0.001), against the background of a decrease in the index of nonspecific reactivity and the ratio of agranulocytes to ESR – by 23.0 (p=0.039) and 15.74% (p=0.044), indicating the onset of specific immunological reactions in the active infectious process. Carriers of the mutational A-allele of the FGB gene (rs1800790) and the TT genotype of the TMPRSS2 gene (rs12329760) showed higher immune reactivity and resistance, which was significantly confirmed by the level of increase in immune reactivity by 6.31-17.21% (p=0.007) and 22.05-35.78% (p≤0.06-0.004), respectively, against the background of a slightly higher rate of allergy (especially in owners of the AG genotype of the FGB gene – by 68.18%, PAG=0.017), a higher ratio of agranulocytes and ESR – by 18.30-21.84% (p≤0.008-0.007) and 19.46-31.07% (p=0.023), with a higher ratio of lymphocytes and eosinophils – by 13.35-19.20% (p≤0.002-0.001). The influence of the wild-type T-allele of the eNOS gene (rs2070744), the A-allele of the FGB gene (rs1800790) and the TT genotype of the TMPRSS2 gene (rs12329760) on the immunological reactivity of the body of a patient with coronavirus infection was revealed.
Dnipro State Medical University
Title: General immunologic reactivity of patients with COVID-19 and its relation to gene polymorphism, severity of clinical course of the disease and combination with comorbidities
Description:
The aim of the study is to identify and evaluate the general immunological reactivity of patients with COVID-19 and its relationship with gene polymorphism, severity of the clinical course of the disease and combination with comorbidities.
A cohort study was conducted involving 204 patients with COVID-19 diagnosed with community-acquired pneumonia of mild, moderate, and severe degrees who also had comorbidities: endocrinopathies (46 patients), cardiovascular diseases (82 patients), and comorbidities of the ENT organs, connective tissue, gastrointestinal tract, chronic kidney disease (CKD), which were grouped into the group "other comorbidities (76 patients).
Among the patients there were 51.
97% (106) women and 48.
03% (98) men.
The average age of patients was 55.
93±8.
75 years.
The polymorphism of the NOS3 (rs2070744), FGB (rs1800790) and TMPRSS2 (rs12329760) genes was determined by real-time polymerase chain reaction (qualitative determination).
The overall immunological reactivity was detected and evaluated based on the analysis of 14 integral leukocyte indices: leukocyte shift index, absolute leukocyte count/erythrocyte sedimentation rate (ESR) ratio index, lymphocyte-granulocyte index, lymphocyte index, immunological resistance and reactivity index, and others.
The overall immunological reactivity of the body of patients with coronavirus infection increases in the presence of the wild-type T-allele of the eNOS gene (rs2070744) in the patient's genotype, especially the CC genotype, by 21.
98-57.
89% (p≤0.
029-0.
001), against the background of a decrease in the index of nonspecific reactivity and the ratio of agranulocytes to ESR – by 23.
0 (p=0.
039) and 15.
74% (p=0.
044), indicating the onset of specific immunological reactions in the active infectious process.
Carriers of the mutational A-allele of the FGB gene (rs1800790) and the TT genotype of the TMPRSS2 gene (rs12329760) showed higher immune reactivity and resistance, which was significantly confirmed by the level of increase in immune reactivity by 6.
31-17.
21% (p=0.
007) and 22.
05-35.
78% (p≤0.
06-0.
004), respectively, against the background of a slightly higher rate of allergy (especially in owners of the AG genotype of the FGB gene – by 68.
18%, PAG=0.
017), a higher ratio of agranulocytes and ESR – by 18.
30-21.
84% (p≤0.
008-0.
007) and 19.
46-31.
07% (p=0.
023), with a higher ratio of lymphocytes and eosinophils – by 13.
35-19.
20% (p≤0.
002-0.
001).
The influence of the wild-type T-allele of the eNOS gene (rs2070744), the A-allele of the FGB gene (rs1800790) and the TT genotype of the TMPRSS2 gene (rs12329760) on the immunological reactivity of the body of a patient with coronavirus infection was revealed.
Related Results
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Expression and polymorphism of genes in gallstones
Expression and polymorphism of genes in gallstones
ABSTRACT
Through the method of clinical case control study, to explore the expression and genetic polymorphism of KLF14 gene (rs4731702 and rs972283) and SR-B1 gene (rs...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...
Clinical manifestations of post-COVID-19 syndrome
Clinical manifestations of post-COVID-19 syndrome
Aim: to assess the prevalence of various clinical manifestations in COVID-19 survivors, depending on the time interval after the disease, clinical severity, and the presence of pol...
COVID impact on pattern of ischemic heart disease in comparable period
COVID impact on pattern of ischemic heart disease in comparable period
Aim: To compare the impact of COVID-19 on pattern of Ischemic Heart Disease in comparable period by assessing the incidence, severity of symptoms and in-hospital mortality of Ische...
Title: Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease; Potential role for systemic inflammation
Title: Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease; Potential role for systemic inflammation
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, parenchymal disease, now considered as fatal disease of the lungs, characterized by pulm...
Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation
Idiopathic pulmonary fibrosis is a risk factor for cardiovascular disease: potential role of KL-6 and systemic inflammation
Abstract
Background
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal disease of the lungs. It is characterized by pulmona...
EVALUATION OF MORTALITY IN COVID-19, BASED ON CBC CHANGES IN COMORBID VS. NON-COMORBID PATIENTS OF KHOST PROVINCE OF AFGHANISTAN
EVALUATION OF MORTALITY IN COVID-19, BASED ON CBC CHANGES IN COMORBID VS. NON-COMORBID PATIENTS OF KHOST PROVINCE OF AFGHANISTAN
Introduction: The COVID-19 pandemic has resulted in more than 248 million confirmed cases and in excess of 5 million deaths globally until November 2021. Many countries are continu...

